Podcasts about Pittock

Autoimmune neurology is a rapidly evolving subspecialty that focuses on neurologic disorders with atypical immune responses. In this episode, Aaron Berkowitz, MD, PhD FAAN, speaks with Sean J. Pittock, MD, an author of the article “Overview and Diagnostic Approach in Autoimmune Neurology,” in the Continuum August 2024 Autoimmune Neurology issue. Dr. Berkowitz is a Continuum® Audio interviewer and professor of neurology at the University of California San Francisco, Department of Neurology and a neurohospitalist, general neurologist, and a clinician educator at the San Francisco VA Medical Center and San Francisco General Hospital in San Francisco, California. Dr. Pittock is the director for the Center for Multiple Sclerosis and Autoimmune Neurology at Mayo Clinic in Rochester, Minnesota. Additional Resources Read the article: Overview and Diagnostic Approach in Autoimmune Neurology Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz Transcript Full transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME.    Dr Berkowitz: This is Dr Aaron Berkowitz, and today, I'm interviewing Dr Sean Pittock about his article, “Introduction to Autoimmune Neurology and Diagnostic Approach”, which he wrote with his colleague, Dr Andrew McKeon. This article is a part of the August 2024 Continuum issue on autoimmune neurology. Welcome to the podcast, Dr Pittock. Could you introduce yourself to our audience?    Dr Pittock: Well, thank you very much, Dr Berkowitz. So, yeah, I'm a neurologist at the Mayo Clinic. I direct the neuroimmunology laboratory with Dr McKeon and Dr Mills here, and I have also been very much involved in the autoimmune neurology section at the American Academy of Neurology.    Dr Berkowitz: So, many of you probably know Dr Pittock - or if you don't know, you've certainly diagnosed diseases that he has described and written about, and so it's a real honor to get to talk to you today and pick your brain a little bit about some of these complex diseases. So, autoimmune neurology is certainly one of the most exciting subspecialties of our field. I feel like when I talk to students and they ask me to make a case for why they should consider neurology as a career, I tell them, “Of course, I have many reasons I love neurology”, but one thing I mention is that, although many other fields of medicine may have made incredible advances as far as treatments, I can't think of too many other fields outside neurology where entirely new diseases have been described since I've been in training and come out of training - and many of those have been in your field of autoimmune neurology. I can think of cases where I've heard you or one of your colleagues on a neurology podcast describing a new antibody, new disease, and a few weeks later, we see that disease and give a patient a diagnosis that had been elusive from other physicians and hospitals. It's a very exciting, gratifying area. It's also daunting, like, every time I go to the AAN and hear one of your colleagues, there's a new disease, and we realize, “Oops! Was I missing that?” or, “Am I going to see this?” And so, hoping to pick your brain a bit today about some of the key concepts and how to keep them in mind so our listeners can recognize, diagnose, and treat these conditions, even if they can't remember every single antibody in your article and all the new ones you and your colleagues will probably discover between now and when this, um, podcast is released. So, before we get into some of the important clinical aspects of these conditions, could you just lay out sort of the broad breaststrokes, the lay of the land of cell-mediated versus antibody-mediated paraneoplastic versus nonparaneoplastic cell surface versus intracellular - how can we sort of organize this area in our minds?    Dr Pittock: Yeah. It's complex, and it's really an evolving story. But the importance, really, from the perspective of the reader and the perspective of the clinician is that we're talking about disorders where we can actually do something - we can actually impact patients.  And we think about the concept of stopping and restoring in neurology now. We're talking about disorders where we have the potential to stop these inflammatory immune-mediated disorders and, potentially, by stopping early, we may be able to restore function - so, a really important new and evolving field in neurology, because you don't want to miss these conditions. Trying to get your head around the complexity of these entities is difficult, but what we've done in this chapter is, really, to try and lay the groundwork for the following chapters, but provide somewhat of a simplistic approach, but a practical approach that really, I think, can help clinicians. So, the way I think of it, a lot of autoimmune neurology really has stemmed from the discovery of antibodies that cause neurological disease, and the examples of those would be going back to myasthenia gravis (with antibodies to the acetylcholine receptor), going back to Lambert-Eaton syndrome. And then, you know, even if you go back to the older traditional paraneoplastic disorders (the Hu, the Ri, the Yo), at the end of the day, you really have two essential entities, if you want to be very simple. The first is disorders that are caused by an antibody, and the second are disorders where the antibodies you detect are not causing the disorder, but they're telling you that there's predominantly a cellular or T-cell mediated attack of the nervous system. And I think thinking about the diseases in those kind of simple terms helps us when we think about what would be the best treatment to use in these types of cases.   Dr Berkowitz: Fantastic. I think that's very helpful. And just to make sure it's clear in the minds of our listeners when we're dividing into these sort of causative antibodies versus antibodies that might be, uh (I don't know if I'm using the word properly), but, sort of epiphenomena (or they're present, but they're not causative) as you said, can you just give some examples of the ones on either side and how making this distinction helps us in practice?    Dr Pittock: Yes. So, antibodies that are causative of disease - I think, you know, the one that I've done a lot of work on is in neuromyelitis optica, where you have antibodies that are targeting a water channel that sits on an astrocyte, and so it causes NMOSD, or what we consider an autoimmune astrocytopathy. And we know that when the antibody binds to the target, many things can happen. So, when aquaporin-4 antibodies bind to aquaporin-4, they can do a lot of things. They can cause internalization, they can activate complement that results in the killing of the cell - but there can be other situations. For example, when NMDA-receptor antibodies bind to the NMDA receptor, then a variety of different things can occur different to water channel autoimmunity - where, for example, the receptor (the NMDA receptor) is downregulated off the cell surface, and that results, to some extent, in the neuropsychiatric phenomenon that we see in NMDA-receptor autoimmunity. And, obviously, when you have a situation where the antibodies are causing the disease, removal of those antibodies, or the reduction in the production of those antibodies, is going to help patients. Now, on the other side, we have antibodies that we detect in the blood or in the spinal fluid, and those antibodies are targeting proteins that are inside the cell - so those antibodies we don't consider as being pathogenic. Now, remember, there are sometimes situations where proteins that are inside the cell occasionally can be available for antibodies to bind at certain situations. So, for example, in the synapse, amphiphysin or the septins, may at times become available. And so, sometimes, there are targets or antibodies that are somewhat in between those two simplistic concepts. But when we're talking about antibodies that are targeting proteins on the inside of the cell, remember that antibodies don't just suddenly occur. There's a whole process of presentation of target antigen at the lymph node, and then both a T- and a B-cell response. The B-cell response potentially produces the antibodies but also triggers and stimulates T-cells, and those T-cells then go on to cause the disease. And those T-cells are very problematic, because those classical paraneoplastic and the newer ones we've described (and many have described) - these are associated with quite severe neurological disability, and they're very, very difficult to treat. And if you ask me, “Where is the holy grail of autoimmune neurology therapeutic research?” It's in trying to actually figure out ways of treating the predominantly T-cell mediated paraneoplastic and autoimmune neurological disorders. We're making great headway in terms of the treatments of the antibody-mediated neurological disorders.   Dr Berkowitz: That's a helpful overview. So, sticking with this framework, you mentioned as sort of the “causative antibody” category and the antibodies that are predominantly for intracellular antigens, but not believed to be causative - I want to make sure I'm understanding this correctly and we can convey it to our listeners - I believe you said in your paper, then, that the antibodies that are predominantly causative are more likely to be associated with conditions that are very treatable, as compared to the intracellular antibodies that are not thought to be causative, as you just said the disability can be irrecoverable or very hard to treat. And I believe another theme in your paper that you brought out is the antibodies that tend to be causative tend to be cell surface and tend to be less likely to be associated with underlying cancer (although not a perfect rule), and the intracellular antigens more commonly associated with cancer in those cases to look very hard for a cancer before giving up. Are those themes that I understand them from your paper properly, or anything else to add there?    Dr Pittock: Yes, I think that that's exactly the message that we were trying to get across, so that's good news that you've picked up on the themes. I think, yeah, in simple terms, remember that when a cytotoxic T-cell identifies the peptide that its T-cell receptor will target, the ultimate outcome is poor, all right? T-cells are like the marines - they don't mess around. Once they find their target, they eliminate that target, and so, it's really difficult to treat those types of diseases if you get them late. And most patients with cytotoxic T-cell mediated paraneoplastic neurological disorders, oftentimes, by the time they get to a center of excellence, the boat has left the dock in many respects - in other words, it's too late. So, you know, I will often see patients, for example, with progressive cerebellar degeneration (say, in the context of Purkinje cell autoantibody type 1 antibodies and a breast cancer), and if those patients are in a wheelchair at the time that I see them, there's very, very little that we can do. So, you really want to try and get that patient into the office, you know, when they're using a cane (or not), and then, potentially, you have the opportunity - using very aggressive immunosuppressive medications - to make a difference. And that is quite different to other scenarios, where, for example, if you have NMDA-receptor encephalitis - as many of the readers will know, this is a condition that is very treatable, and most patients do very well, because the antibodies, they're disrupting function, but they're not killing the neuron, as we see in those more aggressive, paraneoplastic cytotoxic T-cell mediated diseases.   Dr Berkowitz: Also, in terms of searching for an underlying cancer, another theme in your paper as I understood (but want to make sure I'm understanding and conveying to our listeners and hear your thoughts), that the cell surface and treatable antibody-mediated syndromes, as you mentioned (NMO, NMDA) tend to be less associated with underlying cancers (although can be), whereas the intracellular antigens, um, a much higher percentage of those patients are going to end up having underlying cancers. Is that correct, or any notable exceptions to be aware of in that framework?    Dr Pittock: Yeah, I think the major exception to the rule for the antibodies that are targeting intracellular antigens is the GAD65 antibody story. We generally don't consider the stiff person syndrome, cerebellar ataxia, or other autoimmune neurological disorders associated with very high levels of GAD65 antibodies - those are generally not paraneoplastic. And then there are always exceptions on both sides. You know, one of the benefits of understanding the implications of certain antibodies is trying to understand, you know, what is the likelihood of identifying a malignancy, which antibodies are high-risk antibodies (in other words, high-risk paraneoplastological disorders), and which are low risk in terms of cancer? And, you know, age and the demographic of the individual is often important, because we know, for example, with NMDA-receptor antibodies, the frequency of ovarian teratoma varies with the age of the patient.   Dr Berkowitz: Fantastic. And we encourage our listeners to read your articles – certainly, some very helpful tables and figures that help to elucidate some of these broad distinctions Dr Pittock is making - but just to summarize for the antibody-related part of autoimmune neurology, we have one category of cell-surface antibodies and another of intracellular antibodies. Both can cause very severe and varied neurologic presentations, but the cell surface tend to be more treatable, less likely to be associated with the underlying cancer, and the intracellular less treatable, more likely to be associated with the underlying cancer - but, as with everything in neurology and medicine, exceptions on both sides. Is that a fair aerial view of some of the details we've discussed so far, Dr Pittock?    Dr Pittock: Yeah, I think so. I mean, I also think that, you know, not only, at least, for the antibody-mediated disorders (you know, as we discussed) we have drugs that will reduce the production of those antibodies, but we're also learning a lot more about the cytokine and chemokine signatures of these disorders. For example, NMO, water-channel antibody-mediated diseases are associated with elevated levels of IL-6. We know, for example, in LGI1 encephalitis and other encephalitides, that IL-6 also is elevated at the time of that encephalitic process. And so, the potential to target IL-6 with, you know, drugs that inhibit IL-6 and the IL-6 receptor, these potentially have, you know, a role to play in the management of these types of patients - whereas in the T-cell mediated disorders, you know, no advance has been made in the treatment of those conditions, I would say, in over 50 years. So, for example, the standard of treatment is steroids and then drugs that impact the bone marrow, and so we really haven't moved forward in that respect. And that, I think, is an area that really needs drive and enthusiastic out-of-the-box thinking so that we can try to get better treatments for those patients.   Dr Berkowitz: This has been a helpful overview. I look to dive into some of the scenarios that frontline practitioners will be facing thinking about these diseases. An important point you make in your article is that autoimmune and antibody-mediated neurologic syndromes can affect any level of the neuraxis. Even just our discussion so far, you've talked about anti-NMDA receptor encephalitis, you've talked about myasthenia gravis (that's at the neuromuscular junction), you've talked about paraneoplastic cerebellar degeneration - there can be an “itis” of any of our neurologic structures and that “itis” can be antibody-mediated. So, one of the key messages you give us is, one, that these are sort of in the differential diagnosis for any presenting neurologic syndrome, and, two, sort of one of the key features of the history, really, to keep in mind (since we could be anywhere along the neuraxis) is the subacute presentation when this should really sort of be top of mind in our differential diagnosis - so, many of these patients are going to be mystery cases at the outset. And one striking element you bring out in the paper is that, sometimes, the MRI, CSF, electrophysiology studies may be normal or nonspecifically abnormal, and although it's very helpful when we can send these antibody panels out, in some cases, resources are limited or institutions have certain thresholds before you can send these out (because neurologists love to send them in). Sometimes, they are not necessarily appropriate. So, love to hear your thoughts on when we should be sending these panels. What are some clues? Um we have a subacute neurologic presentation at any level of the neuraxis, and when it's not anti-NMDA receptor encephalitis, that is sort of a clear phenotype in many cases. How you would approach a patient, maybe, where the MRI is either normal or borderline abnormal (or people are squinting at the medial temporal lobe and saying, “Maybe they're a little brighter than normal”), CSF is maybe normal or nonspecifically, um, and the protein is a little high, but no cells? What clues do you use to say, you know, “These are the patients where we should be digging deep into antibody panels and making sure these are sent and not miss this diagnosis?”    Dr Pittock: Well, thank you. That's a good question. So, I think, you know, first of all, these are complex cases. So, the patient is sitting in front of you and you're trying to figure out, first of all, Is this a hardware or a software problem? Are we definitively dealing with an encephalitis or an organic neurological entity that's immune-mediated? And, you know, the way I think of it is, for me, you see a patient, it's a twenty-five-piece jigsaw puzzle and you've got two pieces, and you're trying to say, “Well, if I step back and look at those two pieces, do I have any sense of where we're going with this patient?” So, the first thing you need to do is to collect data, both the clinical story that the patient tells you (and I think you make the good point that that subacute onset is really a big clue), but subacute onset, also fluctuating course, sometimes, can be important. The history of the patient - you know, Is the patient somebody who has a known history of autoimmune disease? Because we know that patients that have thyroid autoimmunity are more likely to have diabetes, they're more likely to have gastrointestinal motility or dysmotility, they're more likely to have a variety of different immune-mediated conditions. So, is there a family history or a personal history of autoimmunity? Is the patient at high risk for malignancy? Are there clues that this potentially could be a tumor-initiated immune process affecting the nervous system? The neurological exam also is extremely important because, again, that helps you, first of all, kind of define and get some objectivity around what you're dealing with. So, does the patient have hyperreflexia? Are there signs that there is neurological involvement? And then, really, what I think we need to do is to try and frame the predominant neurological presentation. So, what is the major issue? Because a lot of these patients will have multiple complaints, multiple symptoms, and it's very important to try and identify the major presentation. And that's important, because the neural autoantibody tests are now presentation-defined - in other words, they're built around the neurological presentation, because the old approach of just doing, apparently, a plastic evaluation is gone, because we've got to a stage where we have now so many neural antibodies, you can't test every single neural antibody. So, if you're suspecting that there may be an autoimmune neurological component, then you really need to think about what would be the most appropriate comprehensive evaluation I need to do for this patient. So, for example, if a patient comes in with a subacute-onset encephalopathy, you're probably going to want the autoimmune encephalitis evaluation, and then you have to pick whether it's going to be serum or spinal fluid - and as we outlined in the paper, there are certain antibodies that are better detected in serum versus spinal fluid. So, for example, in adults over the age of 50, LGI1 is much more accurately detected in serum than spinal fluid, and the absolute opposite is true for NMDA-receptor antibody detection. One of the most important components of the neurological evaluation is the spinal fluid, but actually looking at the white cell count - and in fact, sometimes, it's quite interesting to me that I'll often see patients referred with a diagnosis of encephalitis and autoimmune encephalitis, and yet they haven't had a spinal fluid examination. So, the presence of a white cell count, you know, greater than five is hugely helpful - it's like two pieces of that twenty-five-piece jigsaw, because that really tells you that there is something inflammatory going on. And now, in terms of imaging, you're right - some patients will have normal MRI. And if you really do think that there's evidence of - you know, for example, you do an MRI, but you're getting a good sense that there's a temporal lobe seizure occurring, MRI looks normal, the EEG shows some abnormalities in the mesial temporal area - you know, considering additional imaging modalities (like PET scan of the brain), I think, is reasonable. We know that in NMDA-receptor encephalitis cases, 30% of patients will have normal MRI but they'll often have abnormalities on the PET scans. So, I think, what we do is we try to gather data and gather information that allows us to add in pieces of that jigsaw so that, eventually, after we've done this evaluation, we can see now we have ten pieces. If we step back, we say, “Yes, now we know what this condition is”, and then we essentially plan out the therapeutic approach dependent on what we've found. In terms of identification of underlying malignancy, you know, different people have different approaches. Our approach generally has been to try to get a PET-CT scan of the body as our first go-to test, because, actually, we found that CT chest abdomen and pelvis really actually delivers the same amount of radiation - and from a cost perspective, it's about the same - and we have found that PET-CTs really do provide a higher sensitivity for cancer detection.   Dr Berkowitz: Perfect. A lot of very helpful clinical pearls there. So, in closing, Dr Pittock, I've learned a lot from you today. I'm sure our listeners will as well. What does the future hold in this field? What's coming down the pipeline? What are we going to be learning from you and your colleagues that are going to help us take care of patients with these diseases going forward?    Dr Pittock: Well, thank you, Dr Berkowitz, for that question. I think the future is very bright and very exciting, and, hopefully, some of the more junior members will be enthused by this Continuum series, and, hopefully, we'll go into this area. So, let's talk about the future. The future, I think, is going to be of great interest. Firstly, there's going to be continued discovery of novel biomarkers, and the reasons for that is because of the technical and technological advances we've seen. So, for example, there have been many, many antibodies discovered by us and others that have been discovered on the basis of, for example, phage technology. In fact, the Kelch 11 biomarker discovery in collaboration with UCSF and our group was done on the basis of Joe DeRisi and Michael Wilson's phage approach. And we're actually using that now at Mayo Clinic, and we've discovered about three or four new antibodies just in the last couple of years using this technology (and that here is led by John Mills and Div Dubey). And then, we're also going to see, I think, the evolution of protoarrays much more in biomarker discovery, so, we'll have more antibodies, and again, I think, generally, those antibodies will fall into the two categories we kind of described - so, you know, in terms of the approach to those conditions, maybe not so much change. I do think, though, that the introduction and the utility of comprehensive cytokine and chemokine analysis in the future will assist us in making diagnoses of seronegative encephalitis, but also potentially will direct therapy. So, for example, cytokine A is elevated - maybe that would be a potential target for therapy that's available for these patients with rare and potentially very disabling disorders. Then, when we look at the cytotoxic T-cell mediated disorders, I think the major areas of advance are going to be in better understanding the immunophenotype of cytotoxic T-cell mediated diseases, and then the potential development of tolerization strategies using the specific targets, those specific epitope targets that are involved in paraneoplastic and nonparaneoplastic diseases, and seeing if we can vaccinate patients, but move that immune response into more of a tolerogenic immune response rather than a cytotoxic killing response. And then I think, lastly, we're going to see a dramatic revolution in CAR-T therapeutic approaches to these types of disorders moving forward - and not just, you know, CAR-T therapies that are targeting, you know, CD19 or CD20, but CAR-Ts that are actually personalized and developed so that they can target the specific B- and T-cells in an individual patient and actually do a very fine removal of that autoimmune pathologic process that I think would have significant benefit for patients not only in stopping progression, but also in significantly reducing the potential of side effects - so, a much more targeted approach. So, that's where I think the next ten years is going to be. I think it's very exciting. It's going to require the collaboration of neurologists with, you know, immunologists, hematologists, you know, across the board. So, a very exciting future, I think, for this field.    Dr Berkowitz: Exciting, indeed. And we have learned so much from you and your colleagues at the Mayo Clinic about these conditions, and I definitely encourage our listeners to read your article on this phenomenal issue that really gives us a modern, up-to-date overview of this field and what's coming down the pipeline. So, a real honor to get to speak with you, pick your brain about some of the clinical elements, pitfalls and challenges, and also hear about some of the exciting signs. Thank you so much, Dr Pittock, for joining me today on Continuum Audio.   Dr Pittock: Thank you very much.    Dr Berkowitz: Again, today, I've been interviewing Dr Sean Pittock, whose article with Dr Andrew McKeon on an introduction to autoimmune neurology and diagnostic approach appears in the most recent issue of Continuum on autoimmune neurology. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much to our listeners for joining us today.    Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at Continpub.com/audioCME. Thank you for listening to Continuum Audio.

General Election 2024 - Interviewing Adria Pittock and Jack Abbott - 16th June 2024

You won't agree with everything Dr. Pittock says but hopefully you've considered the possibility that some of your conceptions about Scottish clans are off.  What are some of the misconceptions that are widely held that Dr. Pittock corrects?  What ideas of your own did he challenge?  This episode is sure to stir the pot but I hope you enjoy it and that it is helpful.  Check out Dr. Pittock's books on Amazon (links below)!  They're pretty reasonably priced.  This podcast is also available on Apple Podcasts, Spotify, and a video version is on YouTube. Books:  Scotland: The Global History Culloden: Great Battles The Myth of the Jacobite Clans Celtic Identity and the British Image Jacobitism Scottish Clans YouTube channel Contribute to the Cause! Scottish Clans Website Sponsor:  www.usakilts.com 

Host Justin Barnes, aka the @HITAdvisor, broadcasts from HIMSS24 making this the 10th year of hosting his Live from HIMSS special episodes. On this episode Justin checks in with Tracy Mills, Founder and CEO of J29 Inc, Nick Vass, President of J29 Inc, and Casey Pittock, CEO of SmartMeter. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Welcome back B-oo's crew! This week we head to the pacific northwest and visit the home of legendary portlander Henry Pittock. Once known for being the man behind the oregonian, Henry and his wife Georiana would build a beautiful mansion in their golden years that they would sadly have a limited time to enjoy. Join us as we take a trip back in history to discuss one of the more wholesome hauntings we have covered. Is it the ghost of Henry, or maybe Georgiana...or possibly the spirit of th groundskeeper? Nobody really knows, but everyone agress, that whatever is haunting the home is welcoming. Strap in crew in and get ready to visit the "House On the Hill!"Do you have a story you'd like read or played on the show? Are you part of an investigation team that would like to come on and tell your story and experiences? Maybe you have a show suggestion! Email us at https://gmail.comFollow us on Twitter @fortheboosAnd on Instagram @forthboos-podcastFollow us Tik Tok @fortheboos_podcastYou can also find us on Facebook at For The BoosAnd on YouTube at For The BoosRemember to Follow, Subscribe, and Rate the show...it really does help!For The B-oo's uses strong language and may not be suitable for all audiences, listener discretion is advised!https://linktr.ee/fortheboosSources for rhis episode: Wikipedia.com, oregonencyclopedia.org, pittockmansion.org, allthatsinteresting.com, opb.org, Allthatsinteresting.com, portlandghosts.com, yelp.com, oregonhauntedhouses.com, tripadvisor.com, hauntedus.comAll music and sound effects courtesy of http://www.pixabay.com and freesound.org#paranormal #ghost #haunted #ghosts #paranormalactivity #horror #creepy #paranormalinvestigation #scary #spooky #ghosthunting #spiritual #supernatural #ufo #halloween #spirit #spirits #ghosthunters #podcast #paranormalinvestigator #terror #ghoststories #hauntedhouse #aliens #haunting #alien #supranatural #pengasihan #ghosthunter #ghostadventures

There are so many misconceptions, misunderstandings, and straight up myths regarding the Scottish clans.  For this episode I'm taking comments from Scottish scholar, Prof. Murray Pittock, who teaches at the University of Glasgow.  These comments come from an interview he did on the History Extra Podcast.  Get ready to have some of your current understandings assaulted! Is this content valuable?  You can contribute easily by pitching in the price of a drink at www.scottish-clans.com/team. Want to take your understanding of the Scottish Clans to the next level?  Check out The Origins of the Scottish Clans 101 at www.scottish-clans.com/origins.   Tartan Finder: https://www.lochcarron.co.uk/tartan-finder Link to History Extra Podcast w/ Murray Pittock: https://podcasts.apple.com/us/podcast/scottish-clans-everything-you-wanted-to-know/id256580326?i=1000555926450

Am 16. April 1746 treffen im Moor von Culloden bei Inverness die Jakobiten auf die königstreuen Engländer, um eine endgültige Entscheidung im jahrzehntelangen Thronerbe streit herbeizuführen. Es ist der letzte Versuch der Jakobiten sich gegen die Vereinigung von Schottland und England zu erheben und einen katholischen Stuart zum König zu machen. Der Kampf bei Culloden zwischen den beiden Armeen dauert keine 30 Minuten und doch besiegelt ihr Ausgang das Ende der traditionellen Lebensweise der Highlander......Neun Monate vorher war der letzte Stuart Charles Eduard, genannt Bonnie, in Schottland gelandet und hatte unter seinen jakobitischen Anhängern eine Welle der Euphorie ausgelöst. Der König von Schottland, wie er bald genannt wurde, eilte von Sieg zu Sieg und stieg innerhalb kürzester Zeit zur größten Bedrohung des englischen Königs Georg II. auf. Der aber, hielt eine ganz besondere Trumpfkarte in der Hand. Seinen jüngsten Sohn, den Duke von Cumberland, William Augustus. Er sollte nach der Schlacht bei Culloden von seinen schottischen Feinden nur noch auf eine Weise genannte werden: "the Butcher", der Schlächter. Anmerkung: Nachkommen der Stuarts leben heute noch. In der männlichen Hauptlinie sind sie im Jahr 1807, mit dem Tod von Charlies Bruder Henry Benedict Stuart, ausgestorben.........Das Folgenbild zeigt David Moriers Gemälde "Die Schlacht bei Culloden" (1746).........WERBUNGDu willst dir die Rabatte unserer Werbepartner sichern? Hier geht's zu den Angeboten!........LITERATURPittock, Murray: Great Battles. Culloden, Oxford 2016.Roberts, John L.: "The Jacobite Wars. Scotland and the Military Campagins of 1715 and 1745, Edinburg 2002..........UNTERSTÜTZUNGIhr könnt uns dabei unterstützen, weiterhin jeden 10., 20. und 30. des Monats eine Folge zu veröffentlichen!Folgt und bewertet uns bei Spotify, Google Podcasts, Apple Podcasts, Podimo, Instagram, Twitter oder über eure Lieblings-Podcastplattformen. Über diesen Spendenlink oder unseren Fanartikel-Shop könnt ihr uns auch finanziell unterstützen!Wir freuen uns über euer Feedback, Input und Vorschläge zum Podcast, die ihr uns über das Kontaktformular auf der Website, Instagram und unsere Feedback E-Mail: kontakt@his2go.de schicken könnt. An dieser Stelle nochmals vielen Dank an jede einzelne Rückmeldung, die uns bisher erreicht hat und uns sehr motiviert..........COPYRIGHTMusic from https://filmmusic.io: “Sneaky Snitch” by Kevin MacLeod and "Plain Loafer" by Kevin MacLeod (https://incompetech.com) License: CC BY !Neu! Jetzt hier His2Go unterstützen, Themen mitbestimmen und Quiz2Go mit Moderatorin Chiara erleben! https://plus.acast.com/s/his2go-geschichte-podcast. Hosted on Acast. See acast.com/privacy for more information.

SEO. Three little letters that strike fear in the hearts of so many small business owners. SEO, or Search Engine Optimization, is frequently misunderstood and feared, which is why I am so excited to share this conversation with SEO Coach and Trainer Jason Pittock. Jason enables and equips business leaders and marketing professionals with breakthrough SEO knowledge. Join us as we discuss how your business strategy and SEO should go hand-in-hand, why SEO is not something that you can just turn on and get results immediately, and Jason's professional journey from warehouse employee to running his own SEO and marketing firm. Guest Resourceshttps://jasonpittock.comhttps://twitter.com/pittock_jasonhttps://www.instagram.com/jason.pittockhttps://www.youtube.com/c/JasonPittockMarketinghttps://www.linkedin.com/in/jason-pittock BE IN CHARGE >> TAKE ACTION >> GET RESULTSConquer Your BusinessJoin us on FacebookLinkedInInstagram

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at the 75th American Academy of Neurology Annual Meeting, held April 22-27, 2023, in Boston, Massachusetts. Those included in this week's episode, in order of appearance, are: Michael H. Barnett, MBBS, PhD, FRACP, a consultant neurologist at Royal Prince Alfred Hospital (RPAH) Sydney, director of the RPAH MS Clinic and the MS Clinical Trials Unit at the Brain and Mind Centre; codirector of the MS Research Australia Brain Bank; and a senior professor at the University of Sydney. Nancy R. Foldvary-Schaefer, DO, FAAN, the director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic, and a professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Sean J. Pittock, MD, the director of the Center for Multiple Sclerosis and Autoimmune Neurology and director of the Neuroimmunology Research Laboratory at Mayo Clinic. Katherine W. Turk, MD, a neurologist at Boston VA Memory Disorders Clinic, principal investigator and codirector of the Center for Translational Cognitive Neuroscience lab (CTCN) at VA Boston; and assistant professor of neurology and coleader of the Outreach, Recruitment and Engagement core of the Alzheimer's Disease Research Center at Boston University. Erika U. Augustine, MD, MS, the associate chief science officer and director of the Clinical Trials Unit at the Kennedy Krieger Institute. Jeffrey M. Statland, MD, a neuromuscular disease specialist and professor of neurology at the University of Kansas Medical Center. Chian-Chun Chiang, MD, a stroke and migraine specialist and assistant professor of neurology at Mayo Clinic. Want more from the 75th American Academy of Neurology Annual Meeting? Click here for all of NeurologyLive®'s coverage of AAN 2023. Episode Breakdown: 1:10 – Barnett on the topline findings for CNM-Au8 from the VISIONARY-MS clinical trial. 8:35 – Foldvary-Schaefer on the understanding of the relationship between epilepsy and sleep. 13:25 – Pittock on the latest data on ravulizumab from the CHAMPION-NMOSD trial. 19:00 – Turk on the landscape of diagnosis and treatment for mild cognitive impairment, and how to improve the process. 22:00 – Augustine on Dr. Sidney Carter and the current paradigm of care in child neurology. 27:15 – Statland on the findings for ataluren in nonsense mutation Duchenne muscular dystrophy from Study 041. 34:05 – Chiang on the takeaways from a big data analysis of 25 therapies for acute migraine management. This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Barnett MH. VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 2. Foldvary-Schaefer NR. Diagnostic Testing: Beyond the MSLT. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 3. Pittock SJ. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 4. Statland JM. Safety and Efficacy of Ataluren in nmDMD Patients from Study 041, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 5. Chiang CC. Simultaneous Comparisons of 25 Acute Migraine Medications: A Big Data Analysis of 10 Million Patient Self-Reported Treatment Records From A Migraine Smartphone Application. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA.

 (00:31) Can you provide our listeners with a little bit of background on your role at Mayo Clinic? (01:56) Is Ma2 an example of identifying a need in patient care and then creating a test to fill that gap? (02:30) Can you give us an overview of the disease state? (04:29) What makes testing for these antibodies so complex? (07:08) What specimen types are needed? Is there anything else our listeners should know about the assay itself? (08:18) Ma2 will initially be a standalone test. But will these antibodies eventually be included in the movement disorder and encephalopathy tests? (09:30)Is it correct that roughly 80% of these patients have a cancer? (10:41)What types of patients should this testing be ordered for? (13:39)Is rapid onset part of the presentation? (15:53)Should any other testing be ordered in conjunction with Ma2? (17:18)How important is early, aggressive treatment for these patients? (18:49)What are you most excited about with this test launch?

In this wide-ranging, deeply researched account, Murray Pittock examines the place of Scotland in the world. Pittock explores Scotland and Empire, the rise of nationalism, and the pressures on the country from an increasingly monolithic understanding of “Britishness.” From the Thirty Years' War to Jacobite risings and today's ongoing independence debates, Scotland and its diaspora […]

Sean J. Pittock, MD, Director of Mayo Clinic's Center for Multiple Sclerosis and Autoimmune Neurology and of Mayo's Neuroimmunology Laboratory discusses the latest results from Phase III CHAMPION-NMOSD trial recently presented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress. The results showed that treatment with ravulizumab-cwvz significantly reduced relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).NMOSD is a rare central nervous disorder that primarily affects the spinal cord and optic nerves. Symptoms of NMOSD may include blindness in one or both eyes, weakness or paralysis of arms or legs, spasming, loss of sensation, uncontrollable vomiting and hiccups, and bladder/bowel problems due to spinal cord damage. Relapse is very common in persons with NMOSD and episodes can be severe enough to cause permanent disability. As Dr. Pittock explains, the CHAMPION-NMOSD study is a global Phase III, open-label, multicenter trial evaluating the safety and efficacy of ravulizumab in adults with AQP4-Ab+ NMOSD (n-58). The data presented by Dr. Pittock at ECTRIMS showed that no relapses were observed in patients receiving ravulizumab, with a median treatment duration of 73 weeks. Further, 100% of patients receiving ravulizumab remained relapse-free at 48 weeks, compared to 63% of patients in the external placebo arm.To learn more about NMOSD and other rare neurologic disorders, visit checkrare.com/ neurology/

On 2 November 1967 Winnie Ewing shocked the political establishment when she won the Scottish seat of Hamilton for the Scottish National Party. As today's guest, Professor Murray Pittock explains, so began a month that would radically re-shape modern British politics. *** For British politics the 1960s was a testing time. While the country experienced its fabled cultural flowering, it simultaneously had to come to terms with its reduced place in the world. Decolonisation was going ahead at pace. Sterling was losing its power as a currency. In geo-politics Britain did not know where to turn: to the United States, or towards Europe and the EEC. In this episode Murray Pittock shows how Britain was forced to confront all of these issues within the space of one single month. November 1967 opened with a political shock, when the young politician Winnie Ewing won a bi-election for the Scottish National Party. During her campaign she made use of a gripping slogan: ‘Stop the World: Scotland Wants to Get On.' Here was an early sign of something to come. And as the SNP rose north of the border, more trouble was simmering to the south in Westminster. Soon the Chancellor of the Exchequer, James Callaghan, would be obliged to resign. And in Europe, too, Charles de Gaulle was poised to make matters still worse. Professor Murray Pittock is one of Scotland's foremost living historians. He is the Bradley Chair at the University of Glasgow, where he is also Pro-Vice Principal. He is the author of many books, the most recent of which is Scotland: The Global History: 1603 to the Present. Show notes Scene One: 2 November 1967: Winnie Ewing wins the Hamilton by-election a total surprise, with the victory slogan ‘Stop the World: Scotland wants to get on'. Scene Two: 18 November 1967: sterling devalued against the US $ by 14%; Chancellor of the Exchequer resigns. Scene Three: 27 November 1967: UK application to join EEC vetoed for a second time by de Gaulle. Memento: $1 Silver Certificate banknote People/Social Presenter: Violet Moller Guest: Professor Murray Pittock Production: Maria Nolan Podcast partner: Ace Cultural Tours Theme music: ‘Love Token' from the album ‘This Is Us' By Slava and Leonard Grigoryan Follow us on Twitter: @tttpodcast_ Or on Facebook See where 1967 fits on our Timeline

Prompted by the 2020 murder of George Floyd and the nationwide protests that followed, The Oregonian/OregonLive chose to examine this newspaper's racist history. The first installment of the new series looks at the two white men primarily responsible for The Oregonian throughout its first 60 years as a daily paper: Henry Pittock, the publisher and majority owner, and Harvey Scott, the editor and minority owner. “The Oregonian was a racist newspaper,” said Darrell Millner, an emeritus professor at Portland State University and authority on Black history in Oregon, calling the paper both a reflection of a racist society and a force helping to perpetuate it. The overtly racist words Pittock and Scott printed from 1861 to 1919 made Oregon a more hostile place for people of color to live, excusing lynching, supporting segregation, opposing equal rights. They are still honored throughout Portland today as the namesakes for a mountain, mansion, city park, university building, downtown building and two elementary schools. On the latest episode of Beat Check with The Oregonian, editor Therese Bottomly discusses the series, her apology and the future. Bottomly outlines how the newspaper plans to better engage with communities of color going forward. Learn about some of the modern impacts of the newspaper's historically racist coverage, which included supporting segregation and advocating for a discriminatory jury system. Read it all here. The Oregonian/OregonLive would like to hear from you. Please share your comments about this project, provide ideas for future stories or tell us about your experience with racism in Oregon. Contact us at equity@oregonian.com or leave a voicemail at 503-221-8055. Learn more about your ad choices. Visit megaphone.fm/adchoices

Scotland: A Global History (Yale University Press, 2022) by Dr. Murray Pittock presents an engaging and authoritative history of Scotland's influence in the world and the world's on Scotland, from the Thirty Years War to the present day. Scotland is one of the oldest nations in the world, yet by some it is hardly counted as a nation at all. Neither a colony of England nor a fully equal partner in the British union, Scotland's history has often been seen as simply a component part of British history. But the story of Scotland is one of innovation, exploration, resistance—and global consequence. In this wide-ranging, deeply researched account, Murray Pittock examines the place of Scotland in the world. Pittock explores Scotland and Empire, the rise of nationalism, and the pressures on the country from an increasingly monolithic understanding of “Britishness.” From the Thirty Years' War to Jacobite risings and today's ongoing independence debates, Scotland and its diaspora have undergone profound changes. This ground-breaking account reveals the diversity of Scotland's history and shows how, after the country disappeared from the map as an independent state, it continued to build a global brand. This interview was conducted by Dr. Miranda Melcher whose doctoral work focused on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Scotland: A Global History (Yale University Press, 2022) by Dr. Murray Pittock presents an engaging and authoritative history of Scotland's influence in the world and the world's on Scotland, from the Thirty Years War to the present day. Scotland is one of the oldest nations in the world, yet by some it is hardly counted as a nation at all. Neither a colony of England nor a fully equal partner in the British union, Scotland's history has often been seen as simply a component part of British history. But the story of Scotland is one of innovation, exploration, resistance—and global consequence. In this wide-ranging, deeply researched account, Murray Pittock examines the place of Scotland in the world. Pittock explores Scotland and Empire, the rise of nationalism, and the pressures on the country from an increasingly monolithic understanding of “Britishness.” From the Thirty Years' War to Jacobite risings and today's ongoing independence debates, Scotland and its diaspora have undergone profound changes. This ground-breaking account reveals the diversity of Scotland's history and shows how, after the country disappeared from the map as an independent state, it continued to build a global brand. This interview was conducted by Dr. Miranda Melcher whose doctoral work focused on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

Scotland: A Global History (Yale University Press, 2022) by Dr. Murray Pittock presents an engaging and authoritative history of Scotland's influence in the world and the world's on Scotland, from the Thirty Years War to the present day. Scotland is one of the oldest nations in the world, yet by some it is hardly counted as a nation at all. Neither a colony of England nor a fully equal partner in the British union, Scotland's history has often been seen as simply a component part of British history. But the story of Scotland is one of innovation, exploration, resistance—and global consequence. In this wide-ranging, deeply researched account, Murray Pittock examines the place of Scotland in the world. Pittock explores Scotland and Empire, the rise of nationalism, and the pressures on the country from an increasingly monolithic understanding of “Britishness.” From the Thirty Years' War to Jacobite risings and today's ongoing independence debates, Scotland and its diaspora have undergone profound changes. This ground-breaking account reveals the diversity of Scotland's history and shows how, after the country disappeared from the map as an independent state, it continued to build a global brand. This interview was conducted by Dr. Miranda Melcher whose doctoral work focused on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/world-affairs

Scotland: A Global History (Yale University Press, 2022) by Dr. Murray Pittock presents an engaging and authoritative history of Scotland's influence in the world and the world's on Scotland, from the Thirty Years War to the present day. Scotland is one of the oldest nations in the world, yet by some it is hardly counted as a nation at all. Neither a colony of England nor a fully equal partner in the British union, Scotland's history has often been seen as simply a component part of British history. But the story of Scotland is one of innovation, exploration, resistance—and global consequence. In this wide-ranging, deeply researched account, Murray Pittock examines the place of Scotland in the world. Pittock explores Scotland and Empire, the rise of nationalism, and the pressures on the country from an increasingly monolithic understanding of “Britishness.” From the Thirty Years' War to Jacobite risings and today's ongoing independence debates, Scotland and its diaspora have undergone profound changes. This ground-breaking account reveals the diversity of Scotland's history and shows how, after the country disappeared from the map as an independent state, it continued to build a global brand. This interview was conducted by Dr. Miranda Melcher whose doctoral work focused on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. Learn more about your ad choices. Visit megaphone.fm/adchoices

Scotland: A Global History (Yale University Press, 2022) by Dr. Murray Pittock presents an engaging and authoritative history of Scotland's influence in the world and the world's on Scotland, from the Thirty Years War to the present day. Scotland is one of the oldest nations in the world, yet by some it is hardly counted as a nation at all. Neither a colony of England nor a fully equal partner in the British union, Scotland's history has often been seen as simply a component part of British history. But the story of Scotland is one of innovation, exploration, resistance—and global consequence. In this wide-ranging, deeply researched account, Murray Pittock examines the place of Scotland in the world. Pittock explores Scotland and Empire, the rise of nationalism, and the pressures on the country from an increasingly monolithic understanding of “Britishness.” From the Thirty Years' War to Jacobite risings and today's ongoing independence debates, Scotland and its diaspora have undergone profound changes. This ground-breaking account reveals the diversity of Scotland's history and shows how, after the country disappeared from the map as an independent state, it continued to build a global brand. This interview was conducted by Dr. Miranda Melcher whose doctoral work focused on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/european-studies

Scotland: A Global History (Yale University Press, 2022) by Dr. Murray Pittock presents an engaging and authoritative history of Scotland's influence in the world and the world's on Scotland, from the Thirty Years War to the present day. Scotland is one of the oldest nations in the world, yet by some it is hardly counted as a nation at all. Neither a colony of England nor a fully equal partner in the British union, Scotland's history has often been seen as simply a component part of British history. But the story of Scotland is one of innovation, exploration, resistance—and global consequence. In this wide-ranging, deeply researched account, Murray Pittock examines the place of Scotland in the world. Pittock explores Scotland and Empire, the rise of nationalism, and the pressures on the country from an increasingly monolithic understanding of “Britishness.” From the Thirty Years' War to Jacobite risings and today's ongoing independence debates, Scotland and its diaspora have undergone profound changes. This ground-breaking account reveals the diversity of Scotland's history and shows how, after the country disappeared from the map as an independent state, it continued to build a global brand. This interview was conducted by Dr. Miranda Melcher whose doctoral work focused on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/british-studies

Scotland: A Global History (Yale University Press, 2022) by Dr. Murray Pittock presents an engaging and authoritative history of Scotland's influence in the world and the world's on Scotland, from the Thirty Years War to the present day. Scotland is one of the oldest nations in the world, yet by some it is hardly counted as a nation at all. Neither a colony of England nor a fully equal partner in the British union, Scotland's history has often been seen as simply a component part of British history. But the story of Scotland is one of innovation, exploration, resistance—and global consequence. In this wide-ranging, deeply researched account, Murray Pittock examines the place of Scotland in the world. Pittock explores Scotland and Empire, the rise of nationalism, and the pressures on the country from an increasingly monolithic understanding of “Britishness.” From the Thirty Years' War to Jacobite risings and today's ongoing independence debates, Scotland and its diaspora have undergone profound changes. This ground-breaking account reveals the diversity of Scotland's history and shows how, after the country disappeared from the map as an independent state, it continued to build a global brand. This interview was conducted by Dr. Miranda Melcher whose doctoral work focused on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. Learn more about your ad choices. Visit megaphone.fm/adchoices

I was excited to sit down and talk with Casey Pittock, CEO of Smart Meter, to talk about this evolution because he's been working at the front lines of remote patient monitoring for decades including leading the OneSource and Senior Living divisions of Lifeline which had 500,000 subscribers when it was acquired by Philips. His knowledge and experience in this space and the movement from remotely monitoring seniors to remote physiologic monitoring of patients tells an important story of how far we've come and where we're heading. In the interview, along with sharing about his experience with RPM technology and how far we've come, Pittock shares what separates Smart Meter devices from the plethora of other connected blood pressure, glucose, and smart scales out there. Not all devices are created equal and he shares how easy connectivity to those devices is key. Pittock also shares how he sees this market playing out with so many companies and devices entering the space. I also asked him to talk about their work with other RPM companies and their thoughts on providing devices to other RPM companies versus having healthcare organizations use their platform to connect to the devices. Pittock also shares the best patient story he's heard from someone using a Smart Meter RPM device. Then, he finishes off sharing where RPM technology is headed next. Learn more about Smart Meter: https://smartmeterrpm.com/ Find more great health IT content: https://www.healthcareittoday.com/

PFt this week I have no real Explanation, this episode was 2 hours long with more UwUs than I could handle. Kelly, Ivey, Daniel and Dalton talk about the Pittock mansion and Philadelphia City Hall. Follow us! Instagram: @booboispodcast for pictured hints of our next episodes and shamelessly showing our faces! Reddit: Booboispodcast where we post questions and ask for first-hand stories! You can also reach us at BooBoispodcast@gmail.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/boobois/message Support this podcast: https://anchor.fm/boobois/support

After a couple of cool mornings and pleasant days, we're looking at a warming trend through the weekend. Joseph and Kelley are here to break it down and try to see if there is any sign of rain on the horizon. Plus, a preview of an annual picnic at Pittock Mansion.

I have been haunted by the story of the Scottish Jacobites. Even 300 years later their history feels unresolved. Today I spoke with one of the leading experts on Jacobite history, Prof. Murray Pittock to learn how the uprisings came about and how they turned the course of global history. Prof. Pittock's Book:  Culloden (Great Battles)   Murray Pittock (MA D.Litt. Glasgow; D.Phil Oxford)is Bradley Professor and Pro Vice-Principal. He has worked at the universities of Manchester (where he was the first professor of Scottish literature at an English university), Edinburgh, Oxford, Aberdeen and Strathclyde, and has held visiting appointments at the Centre for Advanced Welsh and Celtic Studies (2002), New York University (Visiting Professor of English, 2015); Charles University, Prague (Ministry of Education Visiting Professor in Languages, 2010), Trinity College, Dublin (Visiting Professor in English and History, 2008), Auburn (History and Equality and Diversity, 2006), Notre Dame (NEH seminar visiting scholar in Irish Studies, 2014), USC (Roy Lecturer in Scottish Studies, 2015) and Yale (Senior Warnock Fellow, 1998 and 2000-1). Murray is a Fellow of the Royal Society of Edinburgh, the English Association, the Royal Historical Society, the Royal Society of Arts and the Society of Antiquaries of Scotland among other bodies, and an honorary Fellow of the Association for Scottish Literary Studies. Murray's books are set on courses in English, History, Irish Studies, theology and politics in around twenty-five countries, and he has been awarded or shortlisted/nominated for a number of literary and historical prizes and prize lectureships. He is one of the few UK academics to be a prize lecturer of both the Royal Society of Edinburgh and the British Academy, and has acted as an external assessor for chairs and grants from the Ivy League to the Middle East. Murray is Scottish History Adviser to the National Trust for Scotland, has acted as adviser to the National Galleries and has held grants in English, History, Museology, Tourism and the creative economy. In 2014, he became the founding convenor of the International Association for the Study of Scottish Literatures, and remains chair of its Trustees. The 2020 Congress is in Prague: https://www.facebook.com/ScotLit2020/. His most recent books include Enlightenment in a Smart City: Edinburgh's Civic Development 1660-1750 (supported by AHRC and Royal Society of Edinburgh, 2018); The Scots Musical Museum (supported by AHRC, 2 vols, 2018); Culloden (History Today top 10 titles of the year, House of Commons reading list and Herald book choice, 2016, reprinted 2017); The Reception of Robert Burns in Europe (supported by AHRC, 2014); The Road to Independence? Scotland in the Balance (2014, 1st edition nominated for Orwell Prize, Daily Telegraph referendum reading choice); Material Culture and Sedition (Saltire Research Book of the Year shortlist, 2014); Scottish and Irish Romanticism (supported by AHRC, paperback, 2011); The Edinburgh Companion to Scottish Romanticism (2011); Robert Burns and Global Culture (supported by AHRC, 2011). Murray has won almost 20 grants to work on cultural and public memory, Jacobitism and the redefining of national Romanticisms. Currently he is PI of the £1M AHRC Ramsay Project (https://www.gla.ac.uk/edinburghenlightenment/), the EPSRC-AHRC Immersive Experiences Scottish Heritage Partnership (https://www.gla.ac.uk/schools/humanities/research/informationstudiesresearch/researchprojects/scottishnationalheritage/) and the Scottish Government (Economic Development) contract on Robert Burns and the Scottish Economy.  Murray's former research students are in posts in the UK, US and SE Asia at levels ranging from research assistant to senior management. Two recent PhDs (Michael Shaw, 2014; Craig Lamont, 2015) won the Roy Medal for the best Scottish Studies thesis of the year in successive years. Murray has appeared in the UK and overseas media in over 50 countries on some 1500 occasions to comment on history, literature and current affairs, including scripting and presenting radio series ( The Roots of Scottish Nationalism -Radio 4, 6.25M aggregate audience, 81% UK wide approval rating) and has co-curated a number of exhibitions. He regularly acts as a consultant to national institutions. Murray supervises PhDs in the areas of Burns, Cultural History, Irish Studies, Jacobitism, Romanticism, Scott, Scottish Studies and other fields.

If you run Google Ads, you can't afford to miss this podcast episode where we interview Jason Pittock, the CMO of ClickGUARD.ClickGUARD is a click forensics and IP blocking tool that connects to your Google Ads account and helps you identify and block clicks from fraudulent clicks, click farms, click bots, and just non-converting clicks.This one tool saved our clients nearly 30% of their budget by eliminating fraudulent and non converting clicks.Click “play” and get ready to learn how to trim the fat from your Google ads budget.Join our daily podcast adventures on your favorite podcast app.For more podcast episodes, visit https://thebattleplanmarketingpodcast.buzzsprout.com/Battle Plan Marketing®Next-Level Marketing for ContractorsAnalysis - Strategy - Growthhttps://battleplan-marketing.com/LinkedInhttps://linkedin.com/company/battleplan-marketing

In our third episode of Client Horror Stories, we have Jason Pittock, CMO of ClickGuard, telling us a passionate and gripping story about making huge deals with big fishes while you are still a reckless (and naive) 21-year-old.  Filled up both with a British accent and Argentinian slang, this story takes us to 6 years ago in the streets of Palermo, Buenos Aires. Back then, Jason, who was a very ambitious and smart young man, happened to land this millionaire deal for the company that he was working for and didn't hesitate for a second before he agreed.  From the beginning, we have a feeling that bad luck was chasing him down: A surprisingly pregnant project manager, broken elevators on delivery day, and a fully flooded storage basement were only the first signs the universe sent Jason to tell him to back off. However, being a persevering and responsible person, Jason continued to do everything he could to accomplish this deal until the very end, when a lawsuit for 50% of the job value arrived.  This story includes everything from lawyers with food stains in their shirts, clients stalking you at the beach, and even calling your dad for some advice. Reaching the end, Jason leaves us with some very valuable lessons on boundaries, mental health, and the importance of telling someone to back off when needed. Links:  Jason Pittock ClickGuard Morgan Friedman

In our third episode of Client Horror Stories, we have Jason Pittock, CMO of ClickGuard, telling us a passionate and gripping story about making huge deals with big fishes while you are still a reckless (and naive) 21-year-old. Filled up both with a British accent and Argentinian slang, this story takes us to 6 years ago in the streets of Palermo, Buenos Aires. Back then, Jason, who was a very ambitious and smart young man, happened to land this millionaire deal for the company that he was working for and didn't hesitate for a second before he agreed. From the beginning, we have a feeling that bad luck was chasing him down: A surprisingly pregnant project manager, broken elevators on delivery day, and a fully flooded storage basement were only the first signs the universe sent Jason to tell him to back off. However, being a persevering and responsible person, Jason continued to do everything he could to accomplish this deal until the very end, when a lawsuit for 50% of the job value arrived. This story includes everything from lawyers with food stains in their shirts, clients stalking you at the beach, and even calling your dad for some advice. Reaching the end, Jason leaves us with some very valuable lessons on boundaries, mental health, and the importance of telling someone to back off when needed. Links: Jason Pittock ClickGuard Morgan Friedman

In this week's episode, Abby gets a little spooky and tells the tale of the haunted Pittock Mansion in Portland, Oregon. Listen in as the crew discusses the history of the home as well as its influential owners, Henry and Georgianna Pittock. Stick around for some creepy paranormal accounts from employees and visitors of the historic mansion (now a museum). And remember, don't forget to submit your own personal paranormal or true-crime stories for a future listener episode!Credits:Wikipedia.comNewspaperArchive.comPittockmansion.orgonlyinyourstate.comAllthatsinteresting.comThoughtcatalog.comoregonencyclopedia.orgMusic By:Brokeforfree.comMatt EdwardsEdited By:MichaelNetwork:www.theoracl3network.comWebsite:https://anxiousandafraid.com/Support the show by purchasing our merch!https://www.teepublic.com/stores/anxious-and-afraid-the-pod?ref_id=13121You can also support the show by becoming a Patreon!Join today and get early ad-free episode releases and a shout-out on the show as well as a cool sticker!https://www.patreon.com/anxiousandafraid

Chris Diamond in conversation with Professor Murray Pittock of the University of Glasgow on the 300th anniversary of the birth of Charles Edward Stuart.

TNT Show host John Drummond is back for 2021  to put our questions to a formidable line up of guests.  This week's guest is Professor Murray Pittock, cultural historian and commentator, professor and pro vice principal, University of Glasgow.   Don't forget to subscribe to our podcast channel so you don't miss future episodes  

Pitts and Dan interview Will's younger brother, Luke. He reveals his life goals and lets just say they're exactly what you would expect from a jacked 16 year old aspiring D1 athlete. Dan discovers that finding his dreams and aspirations will take more than just making a podcast.

19 August 2020 marks the 275th anniversary of the Raising of the Jacobite Standard by Charles Edward Stuart at Glenfinnan. Professor Murray Pittock, Trustee and history advisor to the National Trust for Scotland, takes Jackie Bird through this hugely important moment in Scotland's history.

What does it take to have a childless weekend? A lot of preparation and support. Is it worth it? Yes. I believe that as parents we should all take little breaks from our children, with our spouses and without. This past weekend I had a little getaway with my sister to Portland, one of my favorite cities. 

Please be aware the stories, theories, re-enactments and language in this podcast are of an adult nature and can be disturbing, frightening and in some cases offensive. Listener Discretion is advised – there is very adult content ahead and you have been warned. Welcome heathens welcome to the world of the weird and unexplained. I’m your host, Nicole Delacroix and together, we will be investigating stories about the weird, wonderful, unexplained, eerie, scary and down-right unbelievable. There will be tales of ghosts, murder, supernatural beings and unexplained mysteries. So, sit back, grab your favorite drink, relax and prepare to be transported to today's dark Enigma.... And on today’s Dark enigma we’re continuing our foray into the most ghostly of places to visit on your summer vacation, and I know last week I gave you some international flair, but this week we’re bringing it back home. Why? Well because the summer is almost over so any trip has to be close and quick, so we have to bring it back to the states. But before we get into all that, we will be playing our drinking game as always. Please remember the drinking game is only for those of us that are at home and have nowhere else to go tonight. Since today’s episode is dedicated to the great Northwest, any drink associated with Portland or Oregon will be appropriate. If you’re like me, I’m thinking Seattle circa 1998, so grunge, Nirvana and flannel! Alrighty, now for the game part… every time I say mansion that will be a single shot and every time I say Oregon, that’s a double shot. Now that we have the business end out of the way we can jump headfirst into today’s dark enigma… and the story of the very famous and very very haunted Pittock mansion, so let’s hit it my heathens… Henry Pittock, a London-born newspaper publisher, and his wife Georgiana, met and married in Portland in 1860. Henry went on to become one of the wealthiest men in Oregon society, investing in a variety of industries, including railroads, banking, ranching, and mining. He was also an avid climber and outdoorsman. He helped to found Mazamas climbing club, and became part of the first expedition climb Mount Hood. Georgiana was also an active member of society, becoming involved in many cultural organizations and charities, including the Women’s Union and the Ladies Relief Society. She helped to found the Martha Washington Home, a residence for working women. She was also an enthusiastic gardener and was a founding member of the Portland Rose Society and the Portland Rose Festival. In 1909, the Pittocks decided they wanted to build a home in Portland to retire in. They hired the architect Edward T. Foulkes to design the Pittock Mansion from scratch. The forty-six room mansion was built on a hill overlooking Portland, with a French Renaissance exterior. The inside was uniquely designed, with oak-paneled cabinets, marble floors, a huge central staircase, modern amenities like an elevator and dumbwaiter, and, most strikingly, beautiful views of Mount Hood and the Cascade Mountain Range. Foil lines the inside of the entryway ceiling, a nod to Georgianna’s frugal early years, when she had to save foil from old tea containers.

The early days of Portland, Oregon, as told through this interview with Patti Larkin, Curator of the Pittock Mansion. Henry Pittock was the owner of the Oregonian newspaper, who came across on the Oregon Trail and became one of the most influential people in early Oregon.

Pittock Mansion and The Texas eyeball killer In this episode Keisha tells us about the haunted Pittock Mansion in Portland Oregon. The Mansion is haunted by its former owners and has a people car wash. At 13:40 Wes tells us about the Texas eyeball killer. Charles Albright was whore monger from Dallas TX who murdered prostitutes and cut out their eyeballs. Visit us at http://tequilaandterror.com

Dive into Portland history at The Pittock Mansion with Jennifer Gritt, who talks about all things Pittock; what a fascinating family. The mansion was built using local and regional materials, Pittocks ideas were state of the art. The mansion is open to visitors. Don't miss it!

Episode 86: Haunted Mansions – Pittock (Portland, OR) and Stickney (Bull Valley, IL) Noelle walks us through two Haunted Mansions: the Pittock Mansion in Portland, OR and the Stickney House in Bull Valley, IL. 1. The Pittock Mansion is a French-Renaissance sandstone chateau in the West Hills of Portland, OR. (We love Portland and we’re always kidding with them!) 2. The house is haunted by its former owners. (Hey, Henry and Georgianna Pittock! We see you!) 3. A paranormal investigator caught an EVP of a man saying “I’m heading back.” (That recording proves that there’s life after death!) 4. The Stickney Mansion is located in Bull Valley in McHenry County, IL. (The house was built in 1865 in the Land of Lincoln!) 5. The house served as quarters for Union soldiers during the Civil War. (It’s also believed that the house was tainted by “devil worshipers” who lived in the house in the 1960s! FUN!) Sweet Dreams. XoxoZzzzzz.

The punch lines found in Kenny Pittock’s work are almost endless. An illustration of a double power point becomes the ‘power couple’, while a drawing of a giant foot carries the tagline ‘good things are a foot’. Pittock’s work is relatable and commands us to look at the minutiae of every life. In this conversation Pittock talks about the organic use of humour in his work, how he didn't attend an art gallery until senior school, and his well-loved ceramic book sculptures. Kenny Pittock is a Melbourne-based artist who works primarily in drawing and ceramics. See more at Art Guide Australia online: https://artguide.com.au/podcast-the-humours-of-kenny-pittock

Hi Guys, Well, we are back once again after another longer than intended absence, and once again we are joined by the almighty Pittock. We have a great show for you this time including some vape articles to muse on, some waffle on genetics and sports and many topics which provide great sources of in-depth waffling goodness for your earholes. Usual sections also included where myself and Bungle round up our recent vape acquisitions also a special nod to Vapouraound magazine who featured yours truly in the "Diary of a Vaper" section in their latest issue. As usual, the music is provided courtesy of OC Remix and links to the tracks used will be further down. Hope you all enjoy what is a very fun show. New Vape Gear Toppers:Recoil Rebel RDA - https://recoilrda.com/collections/atomizers/products/reloaded-rda?variant=32662555905Dead Rabbit RDA - https://www.ecigone.co.uk/hellvape-dead-rabbit-rda-designed-by-heathenKylin RTA - https://greyhaze.co.uk/products/kylin-rta-by-vandy-vape-special-edition-grey-haze-exclusive?variant=37197657097Anarchist Riot RDA - https://www.evolutionvaping.co.uk/riot-rda-by-anarchist.html Mods:Lost Vape Therion 166 - https://greyhaze.co.uk/products/lost-vape-therion-dual-18650-dna166-box-modSilver Steam Titan V2 - https://silversteamvapor.com/products/titan-v2-custom-enclosureVoopoo Drag - https://www.ecigone.co.uk/voopoo-drag-157w-black-editionTesla Steampunk Nano - https://www.ecigone.co.uk/tesla-nano-steampunk-nano-modPurge Twizted Mod - https://www.superiorvapour.com/products/twizted-mod-by-purge-mods Articles Vape Interest:https://www.vapingpost.com/2017/10/03/new-jersey-state-trying-to-ban-flavors-for-3rd-time/https://www.vapingpost.com/2017/10/05/study-shows-the-danger-in-banning-e-cigarette-flavours/https://www.vapingpost.com/2017/10/04/ny-lawmaker-wants-to-ban-flavoured-e-liquids-in-the-state/https://www.vapingpost.com/2017/10/12/uk-study-recommends-e-cigs-as-smoking-cessation-tools/ Music OC Remix - https://ocremix.org/ Track 1 - Modrem Stomp (Guild Wars 2 Remix) by DusK - https://ocremix.org/remix/OCR03496Track 2 - Psy Castle (super Mario Land Remix) by B-laze - https://ocremix.org/remix/OCR03496 Special Mention: Vapouraound Magazine - https://vapouround.co.uk/Latest Issue No 13 (with the article featuring me) - https://view.joomag.com/vapouround-magazine-issue-13/0628534001506440900

This time on the podcast we are joined by DM extraordinaire, master of the bants and good friend Mr. Pittock.We talk a little vape, a little TPD but a lot of films, games and random bollocks, as is our way.We had some quality issues again with Ian's mic, however I did what I could in post. Needless to say that mic is being smashed to shit and replaced with the same ones me and Bungle use so going forward we should see more even quality.Hope you enjoy.ner0kw instagram: https://www.instagram.com/ner0kw/Bungleman instagram: https://www.instagram.com/fidel_castrato/

1) Spectrum of cognition short of dementia and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. David Knopman about his paper on the spectrum of cognition short of dementia. Dr. Ted Burns is interviewing Dr. Terrence Cascino for our “What's Trending” feature of the week about what AAN is doing to combat the trend of physician burnout. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Sean Pittock about the topic of neuromyelitis optica assay development, treatments and mimics, including MOG antibodies. The participants had nothing to disclose except Drs. Jeff Burns, Knopman, Burns, Cascino, Clardy and Pittock.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Knopman served as Deputy Editor for Neurology®; serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer's Disease Cooperative Study; serves as a consultant to the Bluefield Project to Cure Frontotemporal Dementia; and receives research support from the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Cascino serves as President for the American Academy of Neurology.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Pittock receives research support from Alexion, Guthy Jackson Charitable Foundation and the NIH.

Utility of an immunotherapy trial in the evaluation of patients with presumed autoimmune epilepsy and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Sean Pittock about his paper on the utility of an immunotherapy trial in the evaluation of patients with presumed autoimmune epilepsy. Dr. James Addington is reading our e-Pearl of the week about logopenic-variant primary progressive aphasia. In the next part of the podcast Dr. Mike Brogan interviews Dr. Pratik Pandharipande about delirium in acute brain dysfunction in critically ill patients. The participants had nothing to disclose except Drs. Pandharipande, Pittock and Addington.Dr. Pandharipande received research support from Hospira Inc. and the NIH.Dr. Pittock received research support from Alexion Pharmaceuticals, Inc.; Guthy Jackson Charitable Foundation and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

Interview with Sean J. Pittock, MD, author of Autoimmune Epilepsy: Clinical Characteristics and Response to Immunotherapy and Gregory K. Bergey, MD author of Autoantibodies in the Patient With Drug-Resistant Epilepsy: Are We Missing a Treatable Etiology?

1) Paraneoplastic isolated myelopathy and 2) Topic of the month: Unusual headache syndromes. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Drs. Erik Ensrud and Isabel Arrilaga-Romany interviews Dr. Sean Pittock about his paper on paraneoplastic isolated myelopathy. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about oy-sters in psychogenic non-epileptic seizure diagnosis. In the next part of the podcast Dr. Noah Kolb interviews Dr. Michael Sowell about secondary headaches to conclude this month's theme about unusual headache syndromes. The participants had nothing to disclose except Drs. Pittock and Clardy.Dr. Pittock may accrue revenue for patents re: aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica and aquaporin-4 autoantibody as a cancer marker; and has received research support from Alexion Pharmaceuticals, Inc. and the Guthy Jackson Charitable Foundation.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.